340B Providers Offer Varying Approaches To Tracking, Using Discounts At Hearing

House Energy and Commerce Committee Chair Greg Walden, R-Ore., expresses frustration at lack of reliable data on the way providers account for 340B drug discounts at Oct. 11 hearing.

Capitol House

Hospitals and other health care providers participating in the 340B drug discount program use different approaches to tracking how much they receive in 340B savings and how those savings are used, which points to the need for greater transparency, House Energy and Commerce Committee Chairman Greg Walden, R-Ore., said at an Oversight Subcommittee hearing on the program Oct. 11.

"The lack of transparency requirements has resulted in inconsistent data and dueling reports from every side of the issue," Walden...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Pricing Debate

More from Market Access